2. Search Result
Search Result
Results for "

SMARCA2-IN-2

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-162740
    SMARCA2-IN-2

    		Epigenetic Reader Domain Cancer
    SMARCA2-IN-2 (Compound I-25) is a SMARCA2 inhibitor (IC50: 101-500 μM), and can be used for cancer research .
    SMARCA2-IN-2
  • HY-159543
    (S,R,S)-AHPC-CO-Ph-Ph-CHO

    		E3 Ligase Ligand-Linker Conjugates Cancer
    SMARCA2-ligand-Linker Conjugate-1 is an E3 ligase ligand-linker conjugate.
    (S,R,S)-AHPC-CO-Ph-Ph-CHO
  • HY-153425
    PROTAC SMARCA2 degrader-2

    		PROTACs Cancer
    PROTAC SMARCA2 degrader-2 is a potent and selective SMARCA2/4 PROTAC degrader with an IC50 of <0.1 μΜ in HeLa HiBiT assay. PROTAC SMARCA2 degrader-2 is extracted from patent WO2023287787A1 and has the potential for SMARCA4-related or deficient cancer research .
    PROTAC SMARCA2 degrader-2
  • HY-161889
    DCSM06-05

    		Epigenetic Reader Domain Cancer
    DCSM06-05 is a potent SMARCA2-BRD inhibitor with an IC50 value of 9 µM, a Kd value of 22.4 µM .
    DCSM06-05
  • HY-168230
    SMARCA2 ligand-9

    		Ligands for Target Protein for PROTAC Cancer
    SMARCA2 ligand-9 is the ligand of SMARCA2. SMARCA2 ligand-9 can be used to synthesize PROTAC SMARCA2 degrader-27 (HY-168229) .
    SMARCA2 ligand-9
  • HY-163865
    PROTAC SMARCA2 degrader-13

    		PROTACs Cancer
    SMARCA2 degrader-2 (compound I-322) is a PROTAC degrader targeting SMARCA2; it degrades SMARCA2 proteins in A549 cells with an DC50 <100 nM, and a maximum degradation rate (Dmax%) >90 after 24 h of treatment .
    PROTAC SMARCA2 degrader-13
  • HY-161887
    SMARCA2-IN-8

    		Epigenetic Reader Domain Cancer
    SMARCA2-IN-8 (Compound 13) is an orally active inhibitor for SWI/SNF chromatin remodeling complexe SMARCA2 (also known as Brahma homologue, BRM) and SMARCA4 (also known as Brahma-related gene 1, BRG1) with IC50 of 5 and 6 nM. SMARCA2-IN-8 inhibits the proliferation of SMARCA2 mutated cancer cell SKMEL5 with AAC50 of 5 nM. SMARCA2-IN-8 downregulates the SMARCA2-dependent KRT80 gene expression with AAC50 of 10 nM. SMARCA2-IN-8 exhibits antitumor efficacy and good pharmacokinetic characteristics in mice .
    SMARCA2-IN-8
  • HY-170824
    SMD-3236

    		PROTACs Epigenetic Reader Domain Cancer
    SMD-3236 is a SMARCA2-targeted PRAOTAC degrader designed based on SMARCA ligands and VHL-1 ligands, with long-lasting antitumor activity in vivo. SMARCA2 is a synthetic lethal target in SMARCA4-deficient cancer cells, and SMD-3236 has a 2000-fold selectivity for degradation of SMARCA2 over SMARCA4, with a DC50< 1 nM and a Dmax>95%. SMD-3236 can induce SMARCA2 loss in tumor tissues while retaining SMARCA4 protein, and inhibit tumor growth in the H838 smarca4-deficient human cancer xenograft model. SMD-3236 is composed of target protein ligand (red part) SMI-1074 (HY-170817), PROTAC linker (black part) (trans-4-Ethynylcyclohexyl)methyl methanesulfonate (HY-170825), and E3 ligase ligand (blue part) SMARCA2 ligand-14 (HY-170826), of which the E3 ligase ligand and linker form a conjugate E3 Ligase Ligand-linker Conjugate 159 (HY-170827) .
    SMD-3236

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: